KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $898.9 million.

  • Alnylam Pharmaceuticals' Non-Current Assets rose 579.51% to $898.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 1015.23%. This contributed to the annual value of $944.7 million for FY2024, which is 1151.05% up from last year.
  • Alnylam Pharmaceuticals' Non-Current Assets amounted to $898.9 million in Q3 2025, which was up 579.51% from $922.3 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Non-Current Assets peaked at $945.6 million during Q1 2025, and registered a low of $784.3 million during Q2 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Non-Current Assets averaged around $856.1 million, with its median value being $849.6 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 3539.4% in 2021, then surged by 1313.43% in 2025.
  • Alnylam Pharmaceuticals' Non-Current Assets (Quarter) stood at $834.7 million in 2021, then rose by 2.32% to $854.1 million in 2022, then decreased by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then dropped by 4.85% to $898.9 million in 2025.
  • Its last three reported values are $898.9 million in Q3 2025, $922.3 million for Q2 2025, and $945.6 million during Q1 2025.